--- title: "Aclarion (ACON) stock listing, news and investor profile" url: "https://aibio.space/companies/aclarion/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Aclarion, Inc. (NASDAQ: ACON), United States. Listing facts, related biotech companies and news on aibio.space." --- ACON Aclarion, Inc. NASDAQ · United States # Aclarion (ACON) news Aclarion, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ACON, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Aclarion news We have not published a story on Aclarion yet. When there is news, it will appear here. ## Aclarion at a glance - **Ticker**: ACON - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $16.3 million ### Related companies - [VASO](https://aibio.space/companies/vaso/) OTC: VASO - [Synergy CHC](https://aibio.space/companies/synergy-chc/) OTC: SNYRQ - [ANGIODYNAMICS INC](https://aibio.space/companies/angiodynamics/) NASDAQ: ANGO - [BioXcel Therapeutics](https://aibio.space/companies/bioxcel-therapeutics-btaiq/) OTC: BTAIQ - [ADAPTIN BIO, INC.](https://aibio.space/companies/adaptin-bio/) OTC: APTN - [PAVmed](https://aibio.space/companies/pavmed/) NASDAQ: PAVM - [ALPHA PRO TECH LTD](https://aibio.space/companies/alpha-pro-tech/) NYSE: APT - [PRO DEX INC](https://aibio.space/companies/pro-dex/) NASDAQ: PDEX ### Also on NASDAQ - [BeyondSpring](https://aibio.space/companies/beyondspring/) BYSI - [Seres Therapeutics](https://aibio.space/companies/seres-therapeutics/) MCRB - [Beta Bionics](https://aibio.space/companies/beta-bionics/) BBNX - [Sarepta Therapeutics](https://aibio.space/companies/sarepta-therapeutics/) SRPT - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) CNXU - [EyePoint](https://aibio.space/companies/eyepoint/) EYPT ## Aclarion annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$75,730](https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/) | [$45,724](https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/) | | Research and development | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/) | [$888,766](https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/) | | Net income (loss) | [-$7.2 million](https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/) | [-$7.0 million](https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/) | | Cash from operations | [-$7.2 million](https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/) | [-$5.3 million](https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/) | | Cash and equivalents | [$12.0 million](https://www.sec.gov/Archives/edgar/data/1635077/000168316826006026/) | [$453,661](https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $16.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Aclarion What is the ticker symbol of Aclarion? Aclarion, Inc. trades under the ticker ACON on NASDAQ. Where is Aclarion listed? Aclarion, Inc. is listed on NASDAQ. Which country or territory is Aclarion listed under? Our directory records Aclarion, Inc. under United States. Does aibio.space cover Aclarion? aibio.space lists Aclarion, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What was Aclarion's revenue last year? $75,730 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Aclarion profitable? Aclarion, Inc. reported a net loss of $7.2 million for the fiscal year ended Dec 31, 2025, and used $7.2 million of cash in operations, per its annual report to the SEC. How much does Aclarion spend on research and development? $1.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Aclarion have? $16.3 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Aclarion Members talk about Aclarion (ACON). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ACON on TradingView](https://www.tradingview.com/symbols/NASDAQ-ACON/). ## Listing details Aclarion, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ACON, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Aclarion, Inc. - **Ticker**: ACON - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/aclarion/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aclarion (ACON) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/aclarion/